Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the MK2 Inhibitor ATI-450 in Healthy Subjects: A Placebo-Controlled, Randomized Phase 1 Study

PURPOSE: ATI-450 is an oral, small-molecule inhibitor of the p38α mitogen-activated protein kinase (MAPK)/MAPK-activated protein kinase 2 (MK2) inflammatory signaling pathway. This phase 1, single and multiple ascending dose (SAD, MAD) study evaluated ATI-450 safety, tolerability, pharmacokinetics,...

Descripción completa

Detalles Bibliográficos
Autores principales: Gordon, David, Hellriegel, Edward T, Hope, Heidi Rath, Burt, David, Monahan, Joseph B
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8203602/
https://www.ncbi.nlm.nih.gov/pubmed/34140814
http://dx.doi.org/10.2147/CPAA.S305308

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8203602/
https://www.ncbi.nlm.nih.gov/pubmed/34140814
http://dx.doi.org/10.2147/CPAA.S305308

Ejemplares similares